NASDAQ BCLI opened at $3.01 on Thursday. The firm’s fifty day simple moving average is $3.22 and its two-hundred day simple moving average is $3.28. Brainstorm Cell Therapeutics has a 12-month low of $2.75 and a 12-month high of $4.46. The firm has a market capitalization of $109.82 million, a P/E ratio of -4.43 and a beta of -0.04.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) last released its quarterly earnings results on Monday, March 28th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.03. During the same quarter in the previous year, the business earned ($0.37) earnings per share. On average, analysts forecast that Brainstorm Cell Therapeutics will post -0.6 EPS for the current year.
About Brainstorm Cell Therapeutics (Get Rating)
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
- Get a free copy of the StockNews.com research report on Brainstorm Cell Therapeutics (BCLI)
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.